Sabe M, Sulstarova A, Glangetas A, De Pieri M, Mallet L, Curtis L
Mol Psychiatry. 2024; 30(3):1223-1255.
PMID: 39592825
PMC: 11835720.
DOI: 10.1038/s41380-024-02800-5.
Liu J, Wang Y, Xia K, Wu J, Zheng D, Cai A
Front Neurosci. 2023; 17:1168911.
PMID: 37287797
PMC: 10243528.
DOI: 10.3389/fnins.2023.1168911.
Ley L, Holze F, Arikci D, Becker A, Straumann I, Klaiber A
Neuropsychopharmacology. 2023; 48(11):1659-1667.
PMID: 37231080
PMC: 10517157.
DOI: 10.1038/s41386-023-01607-2.
Hirschfeld T, Prugger J, Majic T, Schmidt T
Neuropsychopharmacology. 2023; 48(11):1602-1611.
PMID: 37161078
PMC: 10516880.
DOI: 10.1038/s41386-023-01588-2.
Bespalov A, van Gaalen M, Steckler T
Adv Neurobiol. 2023; 30:207-224.
PMID: 36928852
DOI: 10.1007/978-3-031-21054-9_9.
Hofmann vs. Paracelsus: Do Psychedelics Defy the Basics of Toxicology?-A Systematic Review of the Main Ergolamines, Simple Tryptamines, and Phenylethylamines.
Henriquez-Hernandez L, Rojas-Hernandez J, Quintana-Hernandez D, Borkel L
Toxics. 2023; 11(2).
PMID: 36851023
PMC: 9963058.
DOI: 10.3390/toxics11020148.
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science.
Schlag A, Aday J, Salam I, Neill J, Nutt D
J Psychopharmacol. 2022; 36(3):258-272.
PMID: 35107059
PMC: 8905125.
DOI: 10.1177/02698811211069100.
Neuropsychological Functioning in Users of Serotonergic Psychedelics - A Systematic Review and Meta-Analysis.
Basedow L, Riemer T, Reiche S, Kreutz R, Majic T
Front Pharmacol. 2021; 12:739966.
PMID: 34603053
PMC: 8481924.
DOI: 10.3389/fphar.2021.739966.
Investigation of the Structure-Activity Relationships of Psilocybin Analogues.
Klein A, Chatha M, Laskowski L, Anderson E, Brandt S, Chapman S
ACS Pharmacol Transl Sci. 2021; 4(2):533-542.
PMID: 33860183
PMC: 8033608.
DOI: 10.1021/acsptsci.0c00176.
Dose-response relationships of psilocybin-induced subjective experiences in humans.
Hirschfeld T, Schmidt T
J Psychopharmacol. 2021; 35(4):384-397.
PMID: 33663259
PMC: 8058832.
DOI: 10.1177/0269881121992676.
The Pharmacology of Visual Hallucinations in Synucleinopathies.
Russo M, Carrarini C, Dono F, Rispoli M, Di Pietro M, Di Stefano V
Front Pharmacol. 2020; 10:1379.
PMID: 31920635
PMC: 6913661.
DOI: 10.3389/fphar.2019.01379.
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
Madsen M, Fisher P, Burmester D, Dyssegaard A, Stenbaek D, Kristiansen S
Neuropsychopharmacology. 2019; 44(7):1328-1334.
PMID: 30685771
PMC: 6785028.
DOI: 10.1038/s41386-019-0324-9.
The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptamines.
Zamberlan F, Sanz C, Martinez Vivot R, Pallavicini C, Erowid F, Erowid E
Front Integr Neurosci. 2018; 12:54.
PMID: 30467466
PMC: 6235949.
DOI: 10.3389/fnint.2018.00054.
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.
Johnson M, Griffiths R, Hendricks P, Henningfield J
Neuropharmacology. 2018; 142:143-166.
PMID: 29753748
PMC: 6791528.
DOI: 10.1016/j.neuropharm.2018.05.012.
The Experience Elicited by Hallucinogens Presents the Highest Similarity to Dreaming within a Large Database of Psychoactive Substance Reports.
Sanz C, Zamberlan F, Erowid E, Erowid F, Tagliazucchi E
Front Neurosci. 2018; 12:7.
PMID: 29403350
PMC: 5786560.
DOI: 10.3389/fnins.2018.00007.
Looking for the Self: Phenomenology, Neurophysiology and Philosophical Significance of Drug-induced Ego Dissolution.
Milliere R
Front Hum Neurosci. 2017; 11:245.
PMID: 28588463
PMC: 5441112.
DOI: 10.3389/fnhum.2017.00245.
Modern Clinical Research on LSD.
Liechti M
Neuropsychopharmacology. 2017; 42(11):2114-2127.
PMID: 28447622
PMC: 5603820.
DOI: 10.1038/npp.2017.86.
Clinical applications of hallucinogens: A review.
Garcia-Romeu A, Kersgaard B, Addy P
Exp Clin Psychopharmacol. 2016; 24(4):229-68.
PMID: 27454674
PMC: 5001686.
DOI: 10.1037/pha0000084.
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.
Halberstadt A
Behav Brain Res. 2014; 277:99-120.
PMID: 25036425
PMC: 4642895.
DOI: 10.1016/j.bbr.2014.07.016.
Effects of hallucinogenic agents mescaline and phencyclidine on zebrafish behavior and physiology.
Kyzar E, Collins C, Gaikwad S, Green J, Roth A, Monnig L
Prog Neuropsychopharmacol Biol Psychiatry. 2012; 37(1):194-202.
PMID: 22251567
PMC: 3294104.
DOI: 10.1016/j.pnpbp.2012.01.003.